Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Peptides. 2011 Aug 22;32(10):2058–2066. doi: 10.1016/j.peptides.2011.08.014

Figure 4. Ikaros deficiency negates VPAC2 upregulation at the DN3 stage.

Figure 4

A. Frequency of putative Ikaros binding sites in the VPAC2 promoter. The Ikaros consensus binding sequences are shown in the forward and reverse directions. B. qRT-PCR measurement of VPAC2 levels in DN3 wild type thymocytes versus JE-131 IK−/− cells. Data is represented as the mean +/− SEM from four independent experiments using four mice each.